PURPOSE: Upregulation of Bcl-2 family members is a well-established mechanism in the development of androgen-independent prostate cancer. Inhibition of the antiapoptotic proteins Bcl-2 and Mcl-1 may delay the transition to androgen-independent growth. EXPERIMENTAL DESIGN: We have established a prostate cancer model with VCaP prostate cancer cells in vivo to study the transition to androgen independence. Here, we investigated the efficacy of AT-101 (R-(-)-gossypol acetic acid; a pan small molecule inhibitor of Bcl-2, Bcl-x(L), and Mcl-1) in combination with surgical castration to delay the onset of androgen-independent growth in vivo. RESULTS: AT-101 (15 mg/kg, per os (p.o.) 5 days/week) in combination with surgical castration delayed the onset of androgen-independent prostate cancer growth in vivo. In addition, we demonstrate the induction of caspase-9-and caspase-3-dependent induction of apoptosis following AT-101 treatment in vitro which was accompanied by an AT-101-induced downregulation of Bcl-2 and Mcl-1 mRNA and protein expression. CONCLUSIONS: We conclude that AT-101 in combination with surgical castration delays the onset of androgen-independent prostate cancer in vivo by disrupting the antiapoptotic activity of Bcl-2 upregulation during the transition to androgen independence. Further studies are needed to define the mechanism of action by which AT-101 attenuates the expression of Bcl-2 and Mcl-1 and to characterize the potential for AT-101 in combination with hormone therapy.
PURPOSE: Upregulation of Bcl-2 family members is a well-established mechanism in the development of androgen-independent prostate cancer. Inhibition of the antiapoptotic proteins Bcl-2 and Mcl-1 may delay the transition to androgen-independent growth. EXPERIMENTAL DESIGN: We have established a prostate cancer model with VCaP prostate cancer cells in vivo to study the transition to androgen independence. Here, we investigated the efficacy of AT-101 (R-(-)-gossypol acetic acid; a pan small molecule inhibitor of Bcl-2, Bcl-x(L), and Mcl-1) in combination with surgical castration to delay the onset of androgen-independent growth in vivo. RESULTS:AT-101 (15 mg/kg, per os (p.o.) 5 days/week) in combination with surgical castration delayed the onset of androgen-independent prostate cancer growth in vivo. In addition, we demonstrate the induction of caspase-9-and caspase-3-dependent induction of apoptosis following AT-101 treatment in vitro which was accompanied by an AT-101-induced downregulation of Bcl-2 and Mcl-1 mRNA and protein expression. CONCLUSIONS: We conclude that AT-101 in combination with surgical castration delays the onset of androgen-independent prostate cancer in vivo by disrupting the antiapoptotic activity of Bcl-2 upregulation during the transition to androgen independence. Further studies are needed to define the mechanism of action by which AT-101 attenuates the expression of Bcl-2 and Mcl-1 and to characterize the potential for AT-101 in combination with hormone therapy.
Authors: L Pegoraro; A Palumbo; J Erikson; M Falda; B Giovanazzo; B S Emanuel; G Rovera; P C Nowell; C M Croce Journal: Proc Natl Acad Sci U S A Date: 1984-11 Impact factor: 11.205
Authors: Yan Shi; Sunanda J Chatterjee; Frank H Brands; Shan-Rong Shi; Llana Pootrakul; Clive R Taylor; Ram Datar; Richard J Cote Journal: BJU Int Date: 2006-01 Impact factor: 5.588
Authors: Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Christopher L Oliver; Joshua A Bauer; Keith G Wolter; Mathew L Ubell; Ajita Narayan; Kathleen M O'Connell; Susan G Fisher; Shaomeng Wang; Xihan Wu; Min Ji; Thomas E Carey; Carol R Bradford Journal: Clin Cancer Res Date: 2004-11-15 Impact factor: 12.531
Authors: Jiahua Jiang; Yasuro Sugimoto; Suling Liu; Hsiang-Lin Chang; Kah-Young Park; Samuel K Kulp; Young C Lin Journal: Anticancer Res Date: 2004 Jan-Feb Impact factor: 2.480
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Mark N Stein; Maha Hussain; Walter M Stadler; Glenn Liu; Irina V Tereshchenko; Susan Goodin; Chandrika Jeyamohan; Howard L Kaufman; Janice Mehnert; Robert S DiPaola Journal: Clin Genitourin Cancer Date: 2015-09-21 Impact factor: 2.872
Authors: Robert S DiPaola; Yu-Hui Chen; Mark Stein; David Vaughn; Linda Patrick-Miller; Michael Carducci; Bruce Roth; Eileen White; George Wilding Journal: J Transl Med Date: 2010-02-24 Impact factor: 5.531
Authors: Aneel Paulus; Kasyapa Chitta; Sharoon Akhtar; David Personett; Kena C Miller; Kevin J Thompson; Jennifer Carr; Shaji Kumar; Vivek Roy; Stephen M Ansell; Joseph R Mikhael; Angela Dispenzieri; Craig B Reeder; Candido E Rivera; James Foran; Asher Chanan-Khan Journal: Br J Haematol Date: 2013-11-17 Impact factor: 6.998